|
Subgroup
|
Variant
|
Chr
|
Position
|
Allelesa
|
AAF
|
Unadjusted analyses
|
Adjusted analyses
|
|---|
|
HR [95% CI]
|
P value
|
BFDP
|
HR [95% CI]
|
P value
|
BFDP
|
|---|
|
Grade 3 tumors
|
rs5934618b
|
X
|
9437463
|
A/G
|
0.08
|
1.39 [1.24,1.56]
|
1.7E-08
|
0.02
|
1.36 [1.21,1.53]e
|
3.0E-07
|
0.17
|
|
rs4830644b
|
X
|
9434808
|
A/G
|
0.08
|
1.39 [1.24,1.56]
|
2.0E-08
|
0.02
|
1.35 [1.20,1.52]e
|
4.8E-07
|
0.23
|
|
rs3810742b, c
|
X
|
9432603
|
T/C
|
0.08
|
1.38 [1.24,1.55]
|
2.0E-08
|
0.02
|
1.35 [1.20,1.52]e
|
4.2E-07
|
0.20
|
|
rs4830642b
|
X
|
9431786
|
T/C
|
0.08
|
1.38 [1.24,1.55]
|
2.9E-08
|
0.02
|
1.35 [1.20,1.52]e
|
5.8E-07
|
0.26
|
|
rs72611496b
|
X
|
9434264
|
G/A
|
0.08
|
1.38 [1.24,1.55]
|
4.3E-08
|
0.03
|
1.34 [1.19,1.51]e
|
1.2E-06
|
0.40
|
|
rs66871326
|
2
|
209048052
|
AAGGAG/A
|
0.76
|
0.85 [0.80,0.90]
|
2.1E-07
|
0.11
|
0.86 [0.81,0.92]e
|
1.8E-06
|
0.49
|
|
ER+ or PR+, and HER2-
|
rs8030394
|
15
|
71637241
|
C/T
|
0.99
|
2.47 [1.81,3.37]
|
1.1E-08
|
0.42
|
2.38 [1.74,3.27]f
|
7.6E-08
|
0.72
|
|
rs112641969
|
15
|
71715016
|
A/G
|
0.02
|
0.46 [0.35,0.61]
|
4.6E-08
|
0.46
|
0.48 [0.36,0.64]f
|
3.7E-07
|
0.78
|
|
rs16955466
|
15
|
71637757
|
C/T
|
0.01
|
0.40 [0.29,0.55]
|
1.5E-08
|
0.49
|
0.42 [0.31,0.58]f
|
1.8E-07
|
0.82
|
|
rs7165279
|
15
|
71636591
|
T/C
|
0.99
|
2.41 [1.77,3.28]
|
2.7E-08
|
0.54
|
2.33 [1.70,3.19]f
|
1.4E-07
|
0.78
|
|
rs111962948
|
15
|
71656213
|
G/T
|
0.01
|
0.41 [0.29,0.56]
|
3.0E-08
|
0.61
|
0.43 [0.31,0.60]f
|
5.6E-07
|
0.91
|
|
rs112813972
|
15
|
71577932
|
T/C
|
0.02
|
0.40 [0.28,0.55]
|
4.0E-08
|
0.70
|
0.42 [0.30,0.59]f
|
3.7E-07
|
0.90
|
|
ER+ or PR+, and HER2- treated with CT
|
rs62192052
|
2
|
230372348
|
C/T
|
0.02
|
0.15 [0.08, 0.28]
|
2.6E-09
|
0.99
|
0.15 [0.08, 0.29]g
|
5.5E-09
|
0.99
|
|
rs74423556c
|
2
|
230325234
|
C/G
|
0.02
|
0.16 [0.08,0.30]
|
2.1E-08
|
0.99
|
0.16 [0.08,0.31]g
|
3.8E-08
|
1.00
|
|
rs145983608
|
2
|
230296944
|
A/G
|
0.02
|
0.15 [0.08,0.30]
|
3.8E-08
|
1.00
|
0.15 [0.08,0.31]g
|
1.1E-07
|
1.00
|
|
ER+ or PR+, and HER2- not treated with CT
|
rs56248395b
|
11
|
20084391
|
C/T
|
0.13
|
2.33 [1.72,3.15]
|
4.8E-08
|
0.59
|
2.23 [1.66,2.99]g
|
1.2E-07
|
0.69
|
|
ER+ treated with ET
|
rs4679741
|
3
|
155003603
|
T/G
|
0.49
|
1.18 [1.11,1.26]
|
1.6E-07
|
0.09
|
1.20 [1.13,1.28] h
|
1.1E-08
|
0.01
|
|
ER- treated with CT
|
rs78754389d
|
4
|
35962454
|
G/A
|
0.07
|
1.79 [1.46,2.20]
|
1.7E-08
|
0.07
|
1.67 [1.39,2.00] i
|
4.1E-08
|
0.09
|
|
rs1106333
|
3
|
14562127
|
C/A
|
0.06
|
1.68 [1.39,2.03]
|
5.6E-08
|
0.12
|
1.70 [1.41,2.05] i
|
4.4E-08
|
0.11
|
|
rs117685664d
|
8
|
26989084
|
C/T
|
0.03
|
0.26 [0.16,0.42]
|
4.6E-08
|
0.97
|
0.50 [0.35,0.70]i
|
6.4E-05
|
0.99
|
|
Tamoxifen
|
rs72775397d
|
5
|
94266932
|
C/T
|
0.28
|
1.36 [1.21,1.53]
|
1.8E-07
|
0.11
|
1.11 [1.03,1.19]j
|
6.6E-03
|
1.00
|
|
Anthracylines
|
rs34072391
|
7
|
30243729
|
C/CA
|
0.52
|
1.27 [1.17,1.39]
|
6.2E-08
|
0.04
|
1.26 [1.15,1.37]k
|
3.4E-07
|
0.16
|
- Abbreviations: Chr chromosome, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, ET Endocrine therapy, CT chemotherapy, AAF alternative allele frequency, HR hazard ratio, CI confidence interval, BFDP Bayesian False Discovery Probability
- Note: BFDP is computed assuming the prior probability of true association equal to 10-4for all variants, which implies a number of expected true associations in the order of 102. Results with BFDP<0.15 in the adjusted analyses are bolded. aReference/Alternative alleles, bAnalyses only include OncoArray data since the variants had imputation r2 <0.7 on iCOGS. More detailed analyses are reported in Table 2 and Supplementary Table 7, cVariant genotyped on OncoArray, dFrom the 5-years breast cancer specific survival analysis, eAdjusted for age at diagnosis, lymph node status, tumor size, distant metastases status, ER status, HER2 status, (neo)adjuvant CT, fAdjusted for age at diagnosis, lymph node status, tumor size, tumor grade, distant metastases status, and (neo)adjuvant CT, gAdjusted for age at diagnosis, lymph node status, tumor size, and tumor grade, hAdjusted for age at diagnosis, lymph node status, tumor size, tumor grade, HER2 status, (neo)adjuvant CT, iAdjusted for age at diagnosis, lymph node status, tumor size, tumor grade, and HER2 status, jAdjusted for age at diagnosis, lymph node status, tumor size, tumor grade, HER2 status ,and (neo)adjuvant CT, kAdjusted for age at diagnosis, lymph node status, tumor size, tumor grade, ER status, and HER2 status
